
Sign up to save your podcasts
Or


Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
By Venrock, a venture capital firm4.8
6262 ratings
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.

1,296 Listeners

2,672 Listeners

2,461 Listeners

1,105 Listeners

341 Listeners

337 Listeners

394 Listeners

5,610 Listeners

10,254 Listeners

34 Listeners

551 Listeners

21 Listeners

300 Listeners

475 Listeners

1,480 Listeners